Issue 2/2019
Content (22 Articles)
Methionine gamma lyase from Clostridium sporogenes increases the anticancer effect of doxorubicin in A549 cells and human cancer xenografts
V. S. Pokrovsky, N. Yu Anisimova, D. Zh Davydov, S. V. Bazhenov, N. V. Bulushova, G. B. Zavilgelsky, V. Y. Kotova, I. V. Manukhov
Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2
Tomoko Takimoto-Shimomura, Taku Tsukamoto, Saori Maegawa, Yuto Fujibayashi, Yayoi Matsumura-Kimoto, Yoshimi Mizuno, Yoshiaki Chinen, Yuji Shimura, Shinsuke Mizutani, Shigeo Horiike, Masafumi Taniwaki, Tsutomu Kobayashi, Junya Kuroda
Euphol, a tetracyclic triterpene, from Euphorbia tirucalli induces autophagy and sensitizes temozolomide cytotoxicity on glioblastoma cells
Viviane A. O. Silva, Marcela N. Rosa, Vera Miranda-Gonçalves, Angela M. Costa, Aline Tansini, Adriane F. Evangelista, Olga Martinho, Adriana C. Carloni, Chris Jones, João Paulo Lima, Luiz F. Pianowski, Rui Manuel Reis
Alteration of benzo(a)pyrene biotransformation by resveratrol in ApcMin/+ mouse model of colon carcinogenesis
Ashley C. Huderson, P. V. Rekha Devi, Mohammad S. Niaz, Samuel E. Adunyah, Aramandla Ramesh
Inhibition of SHP2 by new compounds induces differential effects on RAS/RAF/ERK and PI3K/AKT pathways in different cancer cell types
Cijo George Vazhappilly, Ekram Saleh, Wafaa Ramadan, Varsha Menon, Aya Mudhafar Al-Azawi, Hamadeh Tarazi, Hajjaj Abdu-Allah, Abdel-Nasser El-Shorbagi, Raafat El-Awady
The marine natural product Scalarin inhibits the receptor for advanced glycation end products (RAGE) and autophagy in the PANC-1 and MIA PaCa-2 pancreatic cancer cell lines
Esther Amalia Guzmán, Tara Peterson Pitts, Maria Cristina Diaz, Amy Elizabeth Wright
Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor
James J. Harding, Todd M. Bauer, Daniel S. W. Tan, Philippe L. Bedard, Jordi Rodon, Toshihiko Doi, Christian Schnell, Varsha Iyer, Fabienne Baffert, Rajkumar Radhakrishnan, Claire Fabre, Dejan Juric
A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor
Ciara M. Kelly, Alexander N. Shoushtari, Li-Xuan Qin, Sandra P. D’Angelo, Mark A. Dickson, Mrinal M. Gounder, Mary Louise Keohan, Chloe Mcfadyen, Ana Sjoberg, Samuel Singer, Ronald P. DeMatteo, Sinchun Hwang, M. H. Heinemann, Jasmine H. Francis, Cristina R. Antonescu, Ping Chi, William D. Tap
Phase I study of S-1 plus paclitaxel combination therapy as a first-line treatment in elderly patients with advanced non-small cell lung cancer
Yusuke Chihara, Koji Date, Yoshizumi Takemura, Nobuyo Tamiya, Yoshihito Kohno, Tatsuya Imabayashi, Yoshiko Kaneko, Tadaaki Yamada, Mikio Ueda, Taichiro Arimoto, Junji Uchino, Yoshinobu Iwasaki, Koichi Takayama
A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma
Tycel Phillips, Paul M. Barr, Steven I. Park, Kathryn Kolibaba, Paolo F. Caimi, Saurabh Chhabra, Edwin C. Kingsley, Thomas Boyd, Robert Chen, Anne-Sophie Carret, Elaina M. Gartner, Hong Li, Cindy Yu, David C. Smith
A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors
Khalid Jazieh, Julian Molina, Jacob Allred, Jun Yin, Joel Reid, Matthew Goetz, Vun-Sin Lim, Scott H. Kaufmann, Alex Adjei
Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer
Laura W. Goff, Nilofer S. Azad, Stacey Stein, Jennifer G. Whisenant, Tatsuki Koyama, Ulka Vaishampayan, Howard Hochster, Roisin Connolly, Amy Weise, Patricia M. LoRusso, Safia N. Salaria, Wael El-Rifai, Jordan D. Berlin
Pazopanib with low fat meal (PALM) in advanced renal cell carcinoma
Melissa A. Reimers, Maryann M. Shango, Stephanie Daignault-Newton, Rachel Dedinsky, Danielle Karsies, Shawna Kraft, Liam Riddle, Jeremy A. Felton, Bo Wen, Christina Gersch, James M. Rae, Bruce G. Redman, Ajjai S. Alva
Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer
Pedro C. Barata, Matthew Cooney, Prateek Mendiratta, Ruby Gupta, Robert Dreicer, Jorge A. Garcia
A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer
Kei Saito, Hiroyuki Isayama, Yousuke Nakai, Naminatsu Takahara, Kazunaga Ishigaki, Tsuyoshi Takeda, Ryunosuke Hakuta, Tomotaka Saito, Rie Uchino, Takahiro Kishikawa, Tsuyoshi Hamada, Suguru Mizuno, Takashi Sasaki, Hirofumi Kogure, Saburo Matsubara, Natsuyo Yamamoto, Hideaki Ijichi, Keisuke Tateishi, Minoru Tada, Kazuhiko Koike
Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study
Clinton Yam, Francisco J. Esteva, Miral M. Patel, Akshara S. Raghavendra, Naoto T. Ueno, Stacy L. Moulder, Kenneth R. Hess, Girish S. Shroff, Silvia Hodge, Kimberly H. Koenig, Mariana Chavez Mac Gregor, Robin L. Griner, Sai-Ching J. Yeung, Gabriel N. Hortobagyi, Vicente Valero
IMRT combined with S-1 concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a prospective phase II study
Tao Lv, Yujie Wang, Dan Ou, Peiyao Liu, Songbing Qin, Lidan Liu, Pengrong Lou, Xiaoshen Wang
Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinib
Francesco Facchinetti, Letizia Gnetti, Valeria Balestra, Mario Silva, Enrico Maria Silini, Luigi Ventura, Maria Majori, Paola Bordi, Marcello Tiseo
Development of apratoxin S10 (Apra S10) as an anti-pancreatic cancer agent and its preliminary evaluation in an orthotopic patient-derived xenograft (PDX) model
Weijing Cai, Ranjala Ratnayake, Michael H. Gerber, Qi-Yin Chen, Yichao Yu, Hartmut Derendorf, Jose G. Trevino, Hendrik Luesch
Long-term adverse event: inflammatory orbitopathy induced by pembrolizumab in a patient with metastatic melanoma
Charlée Nardin, Sophie Borot, Marie-Astride Beaudoin, Françoise Cattin, Eve Puzenat, Anne-Sophie Gauthier, Franck Schillo, Christophe Borg, François Aubin
Novel N-1 substituted fluoroquinolones inhibit human topoisomerase I activity and exhibit anti-proliferative activity
Lisa M. Oppegard, Justine L. Delgado, Chaitanya A. Kulkarni, Tyrell R. Towle, Delaney E. Hart, Bridget P. Williams, Sarah R. C. Lentz, Beverly J. Norris, Craig M. Flory, Robert J. Schumacher, Daryl J. Murry, Robert J. Kerns, Hiroshi Hiasa
Identification of differentially expressed genes and signaling pathways using bioinformatics in interstitial lung disease due to tyrosine kinase inhibitors targeting the epidermal growth factor receptor
Yuan Lu, Ang Li, Xiaofeng Lai, Jun Jiang, Lihong Zhang, Zhicheng Zhong, Wen Zhao, Ping Tang, Hu Zhao, Xinling Ren